Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Zacks News
Stryker's LIFEPAK CR2 Defibrillator Launch to Boost MedSurg
by Zacks Equity Research
Stryker's (SYK) emergency care department offers a broad range of products and systems.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) has been benefitting from developments like the FDA clearance of the Rad-67 Pulse CO-Oximeter.
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
Management at Accuray (ARAY) sees significant opportunities in China.
Here's Why You Should Buy Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical (VAR) announces the installation of cyclotron for its ProBeam proton therapy system at the Hefei Ion Medical Center in China.
Align Rides on Firm Global Footprint Despite Fierce Rivalry
by Zacks Equity Research
Align's (ALGN) solid performance in the Europe, Middle East and Africa and Asia-Pacific geographies is appreciative.
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson (BDX) announces the FDA premarket approval for Venovo venous stent device.
ABIOMED Impella Data Show Significant Rise in Survival Rates
by Zacks Equity Research
ABIOMED (ABMD) plans to expand products like Impella CP, Impella Connect, Impella 5.5 and Impella RP.
Varian Medical Opens Office in South Africa, Expands in EMEA
by Zacks Equity Research
Varian Medical (VAR) sees a slew of developments in the EMEA region of late.
Here's Why You Should Retain ABIOMED Stock in Your Portfolio
by Zacks Equity Research
Despite cutthroat competition in the niche markets, ABIOMED (ABMD) seems to be well-positioned for growth on strong guidance and solid product portfolio.
Integer Holdings Gets Positive Outlook & B+ Rating From S&P
by Zacks Equity Research
Integer (ITGR) strengthens its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end.
Why Veeva Systems (VEEV) is an Attractive Pick Right Now?
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio is likely to provide it with a competitive edge in the MedTech space.
Here's Why Investors Should Retain NextGen Healthcare Stock
by Zacks Equity Research
Despite aggressive rivalry in the niche space, NextGen (NXGN) will continue to benefit from strong demand for its other NextGen solutions that include Hospitals, EHR and practice management.
Why Is Masimo (MASI) Up 2.5% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts' FollowMyHealth Partners Ephraim McDowell Health
by Zacks Equity Research
Allscripts' (MDRX) FollowMyHealth is an EHR-neutral patient engagement platform that allows patients to stay connected with their physicians.
Fresenius Medical to Make Huge Investments, Competition Rife
by Zacks Equity Research
Fresenius Medical (FMS) is likely to make huge investments in India and China.
Masimo Gets FDA Clearance for Rad-67 Monitoring Device
by Zacks Equity Research
The clearance will enable Masimo (MASI) to provide portable spot-checking monitoring measurements of oxygen saturation and non-invasive hemoglobin.
Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip
by Zacks Equity Research
On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.
BD Remains Confident About LUTONIX DCB Despite FDA Letter
by Zacks Equity Research
Per the recent press release issued by BD (BDX), it seems that the company still has immense confidence on the LUTONIX DCB.
Senseonics Unveils Eversense Bridge Program in the U.S.
by Zacks Equity Research
The Eversense Bridge program aligns with Senseonics' (SENS) strategy of offering innovative yet affordable and hassle-free medical care to diabetic patients.
Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue
by Zacks Equity Research
Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Varian (VAR) Scales New 52-Week High on Solid Prospects
by Zacks Equity Research
The key growth driving factor for Varian (VAR) in the past year has been increasing net sales from major business segments.
HMS Holdings Gains on PI & TPM Solutions, Competition Rife
by Zacks Equity Research
HMS Holdings is consistently boosting margins and profitability on product-yield enhancements and process improvements.
Here's Why You Should Retain Ecolab Stock in Your Portfolio
by Zacks Equity Research
A solid guidance for 2019 and broad product spectrum will provide Ecolab (ECL) a competitive edge in the MedTech space.
Top Ranked Momentum Stocks to Buy for March 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st